PAASHEUVELWEG 25A, AMSTERDAM, P7
Provides Regulatory Update on AMT-130 for Huntington’s Disease
Investor Presentation
Announces Type A Meeting Scheduled with FDA
Announces Third Quarter 2025 Financial Results and Provides Corporate Update
Announces Pricing of Upsized $300 Million Public Offering
Announces Positive Topline Results from Pivotal Phase I/II Study of AMT-130 in Patients with Huntington’s Disease
FY 2025
Q3
Q2
Q1
FY 2024
Prospectus filed pursuant to Rule 424(b)(5)
Registration Statement for Securities to be Offered to Employees
S-3ASR
Additional Proxy Materials
Definitive Proxy Statement
PRE 14A
Initial Statement of Beneficial Ownership
Statement of Changes in Beneficial Ownership
Notice of Proposed Sale of Securities
Amended Schedule 13G - Ownership Report
Schedule 13G - Ownership Report